Evidence map›Paper›PMID 26942732›Full record

ArticleNeurocritical care2016

Vancomycin Pharmacokinetic Parameters in Patients with Hemorrhagic Stroke.

Kathryn A Morbitzer, J Dedrick Jordan, Kelly A Sullivan, Emily A Durr, Casey M Olm-Shipman, Denise H Rhoney

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Neurocritical care, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07410624 (Augmented Renal Clearance in Neurocritical Care Population), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07410624 recruitingnot on this mapstarted 2021, after this paper: background citation

Augmented Renal Clearance in Neurocritical Care Population: A Prospective Multicenter Study

TypeobservationalSponsorUniversity of AlbertaRan2021 to 2026Enrolled512ConditionsTBI (Traumatic Brain Injury), Status Epilepticus, Bacterial Meningitis, Augmented Renal Clearance (ARC)
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Kathryn A MorbitzerDepartment of Pharmacy, UNC Health Care, Chapel Hill, NC, USA.
J Dedrick JordanDepartments of Neurology and Neurosurgery, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
Kelly A SullivanDepartment of Pharmacy, UNC Health Care, Chapel Hill, NC, USA.
Emily A DurrDepartment of Pharmacy, UNC Health Care, Chapel Hill, NC, USA.
Casey M Olm-ShipmanDepartments of Neurology and Neurosurgery, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
Denise H RhoneyDivision of Practice Advancement and Clinical Education, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, 115 Beard Hall, Campus Box 7574, Chapel Hill, NC, 27599, USA. drhoney@unc.edu.
University of North Carolina at Chapel Hill · USUniversity of North Carolina Health Care · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInfections are a common medical complication in hemorrhagic stroke patients, with vancomycin commonly used as empiric therapy. The purpose of this study was to evaluate the pharmacokinetic parameters of vancomycin in hemorrhagic stroke patients.

methodsThis was a retrospective study of adult patients with aneurysmal subarachnoid hemorrhage (aSAH) or intracerebral hemorrhage (ICH) admitted between May 2010 and February 2015 who received vancomycin. Predicted pharmacokinetic parameters based on population data were compared with calculated pharmacokinetic parameters based on serum trough concentrations.

resultsEighty aSAH patients and 66 ICH patients met inclusion criteria. In the aSAH group, the mean dosing regimen was 17.6 ± 4 mg/kg every 12 (8-12) h. The mean measured trough concentration was lower than the predicted trough concentration (9.9 ± 4.1 vs. 19 ± 8.7 μg/mL; p < 0.001). The mean calculated elimination rate constant was higher than the predicted value (0.135 ± 0.04 vs. 0.092 ± 0.03 h(-1); p < 0.001), and the mean calculated half-life was lower than predicted (5.7 ± 1.8 vs. 8.3 ± 2.9 h; p < 0.001). In the ICH group, the mean dosing regimen was 15.9 ± 4.3 mg/kg every 12 (8-12) h. Similarly, the mean measured trough concentration was lower than the predicted trough concentration (10.7 ± 4.6 vs. 17.5 ± 8.5 μg/mL; p < 0.001). The mean calculated elimination rate constant was higher than the predicted value (0.106 ± 0.03 vs. 0.079 ± 0.02 h(-1); p < 0.001), and the mean calculated half-life was lower than predicted (7.2 ± 2.3 vs. 9.6 ± 3.2 h; p < 0.001).

conclusionsPatients with hemorrhagic stroke exhibited pharmacokinetic alterations favoring increased elimination of vancomycin when compared to predicted pharmacokinetic parameters based on population data. This may result in underexposure to vancomycin, leading to treatment failure and other medical complications.

Indexed as

AgedAnti-Bacterial AgentsBacterial InfectionsFemaleHumansIntracranial HemorrhagesMaleMiddle AgedRetrospective StudiesStrokeSubarachnoid HemorrhageVancomycinAnti-Bacterial AgentsVancomycinHemorrhagic strokeIntracerebral hemorrhagePharmacokineticsSubarachnoid hemorrhageVancomycin

Identifiers

PMID26942732
OpenAlexW2292369446

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.